[1] 刘淼, 陈红鸽, 吴荣荣, 等. 索拉非尼治疗肝癌的研究进展[J]. 医药导报, 2009, 28(12): 1562-1564.
[2] 中国抗癌协会肝癌专业委员会,中国抗癌协会临床肿瘤学协会,中华医学会肝病学分会肝癌学组.原发性肝癌规范化诊治专家共识[J].临床肿瘤学杂志,2009,14(3):259-269.
[3] Llovet JM, Bru C, Bruix J. Prognosis of hepatocellularcarcinoma:the BCLC staging classification[J]. Semin Liver Dis, 1999,19(3):329-338.
[4] Strumberg D, Awada A, Hirte H, et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome[J]? Eur J Cancer, 2006, 42(4): 548-556.
[5] Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006[J]. J Clin Onco, 2006, 24(9): 1363-1369.
[6] 闫敏, 潘跃银. 索拉非尼治疗原发性肝癌的不良反应分析[J]. 安徽医药, 2010, 14(9): 1066- 1068.
[7] 庞永慧,黎乐群,张志明, 等. 索拉非尼治疗原发性肝癌不良反应的观察及护理[J]. 现代临床护理,2010,9(4): 20-21.
[8] 王春英,刘英新,胡君丽. 索拉非尼治疗晚期恶性肿瘤患者致不良反应的护理[J]. 实用医药杂志,2010,27(8): 722-723. |
